Market Place
Sourcing Support
Delix Reveals Phase 1 Results Of DLX-001 At ACNP Annual Meeting
12 Dec 2024 //
BUSINESSWIRE
Delix Doses First Patient In Phase 1b Trial For DLX-001 In MDD
04 Dec 2024 //
BUSINESSWIRE
Delix: DoD Grant For Neuroplastogen In Hearing Loss
04 Jun 2024 //
BUSINESSWIRE
Delix DLX-001 Shows CNS Penetration Without Psychoactive Effects In Phase 1
13 May 2024 //
BUSINESSWIRE
Delix Therapeutics Awarded National Institutes of Health Grant
13 Dec 2023 //
BUSINESSWIRE
Delix Presents Interim Data From Phase I Trial of Novel Neuroplastogen
06 Dec 2023 //
BUSINESSWIRE
Delix Therapeutics Announces Completion of 1st Cohort PhI Trial DLX-001
20 Jun 2023 //
PR NEWSWIRE
Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer
12 Jun 2023 //
PR NEWSWIRE
Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001
09 May 2023 //
PR NEWSWIRE
Delix Therapeutics Partners With Cellectricon To Accelerate Drug Discovery
14 Feb 2023 //
PR NEWSWIRE
Delix Therapeutics Expands World-Class Team with First Head of R&D
22 Sep 2022 //
PRNEWSWIRE
Delix Partners with the NIDA to Advance Research on Non-Hallucinogenic Therapies
07 Dec 2021 //
BIOSPACE
Delix snags $70M series A for psychedelic analog trials in 2022
27 Sep 2021 //
FIERCEBIOTECH
Delix Therapeutics Expands Executive Leadership Team
07 Jul 2021 //
PR NEWSWIRE
Delix Therapeutics Expands Executive Leadership Team
07 Jul 2021 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.